Open AccessEmtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence
Author(s) -
Mary Morrow,
Samantha MaWhinney,
Ryan P Coyle,
Stacey S Coleman,
JiaHua Zheng,
Lucas Ellison,
Lane R. Bushman,
Jennifer J. Kiser,
Peter L. Anderson,
José CastilloMancilla
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002981
Subject(s) - viremia , emtricitabine , medicine , odds ratio , confidence interval , viral load , prospective cohort study , human immunodeficiency virus (hiv) , antiretroviral therapy , immunology
Emtricitabine triphosphate (FTC-TP) in dried blood spots (DBS), a measure of short-term antiretroviral therapy (ART) adherence, is associated with viral suppression in persons with HIV (PWH). However, its ability to predict future viremia remains unknown.